Bayer has filed a marketing application in Europe seeking approval for larotrectinib as treatment for TRK fusion cancer. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/bayer_files_marketing_application_for_larotrectinib_1250348AstraZeneca has bumped up its stake in US biotech Moderna, which is pioneering the development of a new class of drugs made of messenger RNA, to nine percent. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/az_ups_stake_in_moderna_1095937Daiichi Sankyo has entered into a clinical trial collaboration agreement with a subsidiary of MSD to evaluate a potential new combination therapy for breast or lung cancers. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/daiichi_to_test_cancer_drug_combo_1252985Shares in UK group Sinclair Pharma shot up nearly 40 percent after it confirmed interest from Chinese firms with regard to a possible take-over. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/chinese_firms_eyeing_up_sinclair_pharma_1243434Rigel Pharmaceuticals has bagged its first FDA approval, with a green light to market Tavalisse for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have failed to respond to previous treatment. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/rigel_bags_first_fda_approval_1232281Brighton, UK-based Enterprise Therapeutics has raised £29 million to help it advance its experimental therapies for respiratory diseases. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/uks_enterprise_therapeutics_raises_29m_1231511Lilly has entered into an agreement to develop Chugai’s OWL833, a oral non-peptidic GLP-1 receptor agonist currently in Phase I for type II diabetes. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/lillys_snaps_up_chugais_experimental_diabetes_drug_1253840Celgene has decided not to exercise its option to license OncoMed's bispecific antibody navicixizumab. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/celgene_walks_away_from_oncomeds_navicixizumab_1252986The Association of the British Pharmaceutical Industry (ABPI) is linking arms with the Academic Health Science Network in a five-year partnership that strives to accelerate uptake of transformative biomedical innovations by the NHS - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/abpi_enters_five-year_partnership_with_ahsn_1252987AstraZeneca is selling rights to its heart failure and hypertension brand Atacand in Europe, in a move that it says will expand its commercial potential in 28 countries. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/astrazeneca_sells_atacand_rights_to_cheplapharm_1245495
